Introduction {#s1}
============

Human pregnane X receptor (PXR), a known transcriptional regulator of important drug-metabolizing enzymes \[e.g., cytochrome p450 3A4 (CYP3A4)\] and transporters (e.g., ABCB1), is a ligand-activated nuclear receptor expressed in the gastrointestinal (GI) tract, where it functions as a xenobiotic sensor ([@B12]). It is well established that constant exposure to xenobiotics is not only capable of producing inflammation and injury ([@B13]; [@B12]) but can also impair immune function ([@B14]), raising the possibility that inappropriate adaptive responses to xenobiotics may contribute to the pathogenesis of immune-mediated inflammatory pathologies, including inflammatory bowel disease (IBD).

IBD is a chronic inflammatory condition of the GI epithelial mucosa that often manifests in childhood, with children comprising 20--25% of the total patient population ([@B3]). IBD is thought to have its origins in an incompletely understood, multifactorial, disease-causing combination of genetic predisposition, aberrant immune response, environmental triggers, and pathologic alterations in the intestinal epithelial barrier and microbiome ([@B7]). A plausible mechanism linking xenobiotic exposure, inflammation, and immune (dys)function was recently explored in animal models of IBD, where evidence from the mouse model suggested a protective, anti-inflammatory effect of PXR activation in the GI tract ([@B8]; [@B4]; [@B1]). The proposed mechanism involves PXR activation leading to suppression of nuclear factor *κ*B, a key component of the inflammatory cascade and a known regulator of the immune response ([@B13]). In children, the interpretation of such gene expression studies may be confounded by ontogeny. Our aim was to test the hypothesis that *PXR* and its target genes (e.g., *CYP3A4*) are underexpressed in the actively inflamed small intestinal tissue of children with Crohn's disease, a type of IBD.

Materials and Methods {#s2}
=====================

These research activities were approved and declared nonhuman-subjects research by the Institutional Review Board of the Children's Mercy Hospital.

 {#s3}

### Tissue Specimens. {#s4}

Archived biopsy tissue samples from the duodenum and terminal ileum (TI) were obtained from patients, 7--17 years old, with Crohn's disease (CD, *n* = 18) and age- and sex-matched non-IBD patients (control, *n* = 12) who had normal-appearing duodenum and TI on esophagogastroduodenoscopy/colonoscopy performed as part of routine care. Diagnosis of Crohn's disease was confirmed by clinical, radiographic, and histopathologic findings. All histopathology slides were independently reviewed by a single, experienced, board-certified pediatric pathologist to ensure presence of inflammation in CD TI, but not CD duodenum or any control tissues. Presence/absence of inflammation was additionally verified by *IL8* and *iNOS* gene expression studies performed on all biopsy samples.

### RNA Extraction and Quantitative Reverse Transcription--Real-Time Quantitative Polymerase Chain Reaction. {#s5}

Total RNA was prepared from four 10-*μ*m sections of archived formalin-fixed paraffin-embedded intestinal biopsy samples using the RNeasy formalin-fixed paraffin-embedded RNA Isolation Kit (Qiagen, Valencia, CA), according to manufacturer's protocol, including on-column DNase I treatment. RNA quantity was determined on a Nanodrop ND-1000 Spectrophotometer. Total RNA (200 ng) was reverse transcribed using the High-Capacity RNA-to-cDNA Kit (Applied Biosystems/Thermo Fisher Scientific). RNA quality was estimated by performing glyceraldehyde 3-phosphate dehydrogenase (*GAPDH)* 3′:5′ assays ([@B5]). RNA integrity is inferred from the ratio of quantities of the two PCR products targeting the 3′ and 5′ ends of *GAPDH* mRNA, which reflects successful reverse transcription across *GAPDH*. Ratios closest to one are indicative of good quality RNA.

Primers for the *3′ GAPDH* assay were 5′ AGTCCCTGCCACACTCAG (forward) and 5′ TACTTTATTGATGGTACATGACAAGG (reverse); 5′ GTGAACCATGAGAAGTATGACAAC (forward) and 5′ CATGAGTCCTTCCACGATACC (reverse) for the *5′ GAPDH* assay. *GAPDH* assays were performed with 2 *μ*l cDNA, 250 nM each forward and reverse primers, and PerfeCta SYBR green SuperMix (Quanta Biosciences, Gaithersburg, MD). Gene expression assays for *PXR* (Hs00243666_m1), *VIL1* (Hs00200229_m1), *CYP3A4* (Hs00604506_m1), *IL8* (Hs99999034_m1), and *NOS2* (Hs01075529_m1) were performed using 2 *μ*l cDNA, TaqMan Gene Expression Assay (Applied Biosystems), and PerfeCTa qPCR SuperMix (Quanta Biosciences). Standard curves were generated using serial dilutions of cDNA plasmids from 10 to 10^8^ copies/*μ*l. Molecule numbers were determined from linear regression of the standard curves. All gene expression assays were performed with triplicate determinations of molecule numbers for each sample. When sample replicates varied more than 0.5 Ct, the assay was repeated in triplicate.

### Data Analysis. {#s6}

Only tissue samples of adequate quality mRNA (i.e., *GAPDH 3′:5′* ratios less than 10) were included in the study analysis. For relative mRNA expression quantification, replicate determinations of molecule numbers were averaged, normalized to the mean of *GAPDH* molecule numbers, and logarithmically transformed, as data were not normally distributed. Differences in normalized, log~2~-transformed, unit-less, relative gene expression were compared between the TI and the duodenum, using a two-tailed paired Student's *t* test. Spearman's correlation and linear regression analyses were carried out to explore relevant associations. All analyses were conducted using SAS version 9.2 (SAS Institute Inc., Cary, NC) and SPSS version 20 (IBM) with a significance limit set at *α* = 0.05.

Results and Discussion {#s7}
======================

mRNA expression patterns of *PXR, CYP3A4*, and *VIL1* observed in our pediatric patient cohorts are presented in [Fig. 1](#F1){ref-type="fig"}. *GAPDH* expression did not differ with age, sex, or location along the small intestine in the CD or the control cohort (data not shown). In children with CD, *PXR* expression was decreased in inflamed TI versus noninflamed duodenum (TI = 1.88 ± 0.89 versus duodenum = 2.5 ± 0.67; *P* \< 0.001), but not in controls (TI = 2.11 ± 0.41 versus duodenum = 2.26 ± 0.61; *P* = 0.52). Likewise, expression of *CYP3A4* was decreased in inflamed TI of children with CD (TI = --0.89 ± 3.11 versus duodenum = 1.90 ± 2.29; *P* = 0.014), but not in controls (TI = 2.46 ± 0.51 versus duodenum = 2.60 ± 0.60; *P* = 0.61). *VIL1* expression \[indicator of epithelial cell integrity ([@B9])\] was also decreased in inflamed TI of children with CD (TI = 3.80 ± 0.94 versus duodenum = 4.61 ± 0.52; *P* \< 0.001), but not in controls (TI = 4.30 ± 0.35 versus duodenum = 4.47 ± 0.40; *P* = 0.29). A positive correlation between *PXR* and *CYP3A4* expression ([Supplemental Fig. 1](http://dmd.aspetjournals.org/lookup/suppl/doi:10.1124/dmd.115.068742/-/DC1)) was observed (*r* = 0.517, *P* = 0.01), as expected, given that *CYP3A* is a known target of *PXR* ([@B11]). Correlation relationships for all genes of interest, across all samples, are summarized in the supplemental documents ([Supplemental Table 1](http://dmd.aspetjournals.org/lookup/suppl/doi:10.1124/dmd.115.068742/-/DC1)). Unexpectedly, a significant correlation between *PXR* and *VIL1* expression was observed across all samples (*r* = 0.780, *P* = 0.01; [Fig. 2A](#F2){ref-type="fig"}), as well as between *CYP3A4* and *VIL1* ([Supplemental Fig. 2](http://dmd.aspetjournals.org/lookup/suppl/doi:10.1124/dmd.115.068742/-/DC1)). Expression of *PXR* ([Fig. 2B](#F2){ref-type="fig"}), *VIL1* ([Fig. 2C](#F2){ref-type="fig"}), and *CYP3A4* ([Fig. 2D](#F2){ref-type="fig"}) correlated inversely with *IL8* (marker of inflammation) in the TI of CD, but not controls. The observed trend in inverse correlation between *IL8* and the genes of interest reached statistical significance for *CYP3A4* (*P* \< 0.01) and approached significance for *PXR* (*P* = 0.06) and *VIL1* (*P* = 0.07) in the inflamed TI of CD ([Supplemental Table 2](http://dmd.aspetjournals.org/lookup/suppl/doi:10.1124/dmd.115.068742/-/DC1)). This inverse correlation was not observed in noninflamed tissues (e.g., control TI).

![Relative gene expression of *PXR* (A), *VIL1* (B), and *CYP3A4* (C) in the TI and the duodenum of children with Crohn's disease (CD; *n* = 18) versus age- and sex-matched controls without IBD (*n* = 12). Mean differences in relative gene expression (triplicate determinations of molecule number per sample, normalized to *GAPDH*, and log~2~-transformed) were compared between the TI and the duodenum in the same children, using a two-tailed paired Student's *t* test (*α* = 0.05).](dmd.115.068742f1){#F1}

![Correlation relationships (Spearman's correlation; *α* = 0.05) in relative gene expression (triplicate determinations of molecule number per sample, normalized to *GAPDH*, and log~2~-transformed) between (A) *PXR* and *VIL1* across all tissue samples (*n* = 30; *r* = 0.78, *P = 0.01*); (B) *PXR* and *IL8* in the TI of CD (*r* = --0.45, *P = 0.06*) and controls (*r* = 0.18, *P = 0.6*), (C) *VIL1* and *IL8* in the TI of CD (*r* = --0.44, *P = 0.07*) and controls (*r* = 0.27, *P = 0.4*), and (D) *CYP3A4* and *IL8* in the TI of CD (*r* = --0.68, *P \< 0.01*) and controls (*r* = 0.21, *P = 0.5*). Crohn's disease (CD) tissue denoted by cross (*n* = 18), control tissue by circle (*n* = 12).](dmd.115.068742f2){#F2}

Our study results demonstrate a significant decrease in *PXR* expression *only* in the inflamed small intestinal tissue (i.e., TI) in children with CD, relative to uninflamed small intestinal tissue from the same children (i.e., duodenum); [Fig. 1A](#F1){ref-type="fig"}. The strength of our study resides in utilization of noninflamed duodenal tissue from each subject as a negative control for that subject, effectively eliminating interindividual genetic variability as a confounding factor in our mRNA analysis. As no difference in *PXR* expression was observed between the TI and the duodenum in age- and sex-matched controls, the observed decrease in *PXR* in the CD TI cannot be attributed to biopsy site location along the small intestinal tract. More probably, the observed decrease represents the effect of inflammation or disease on the intestinal epithelium, and the diverse population of enzymes, proteins, and receptors that reside within it. Taken together, our observations of the differential patterns of expression in *PXR*, *CYP3A4,* and *VIL1* in children with CD raise several important implications.

First, expression of all genes of interest was lower in CD versus controls, implying that disease/inflammation per se have the potential to produce a significant effect on the expression of genes important to drug disposition and response, including drug-metabolizing enzymes (e.g., *CYP3A4*) and presumably transporters (e.g., *ABCB1*). In the case of *CYP3A4*, the observed disease-associated finding could potentially impact intestinal drug biotransformation, and the rate/extent of bioavailability, of perorally administered drugs. This disease effect could be quite dynamic in a given pediatric patient, as the extent of inflammation changes between the time of disease onset/flare and disease remission and mucosal repair. Given apparent age-related differences in biotransformation of certain CYP3A4 substrates (e.g., cyclosporine, tacrolimus, midazolam) ([@B2]), ontogeny could also be an important covariate; although, we did not detect any age-related changes over the investigated age range (7--17yrs).

Second, our observation of decreased *PXR* expression in actively inflamed versus noninflamed tissue in patients with CD suggests that PXR may play a role in the disease phenotype expression of CD, accounting for the pathognomonic skip lesions characteristic of the disease. Potential mechanisms to support the role of PXR in CD pathogenesis can be inferred from animal studies that demonstrate a mutual and reciprocal repression between PXR and NF-*κ*B ([@B4]; [@B8]; [@B13]). Alternatively, given the recent implication of PXR activation in epithelial cell repair mechanisms via the p38 mitogen-activated protein kinase--dependent pathway in mice ([@B10]), our observed decrease in *PXR* ([Fig. 1A](#F1){ref-type="fig"}) may be related to impaired epithelial barrier integrity thought to contribute to the development of IBD. This is supported by our observation of decreased *VIL1* expression (marker of epithelial integrity) in the inflamed CD TI ([Fig. 1B](#F1){ref-type="fig"}).

Although our mRNA data would be strengthened by protein studies, such studies could not be performed, as archived biopsy tissues of limited quantity were used and depleted during the gene experiments described above. A prospective study utilizing fresh biopsy tissue samples from children is underway to address this study limitation.

Herein, we provide preliminary evidence concerning a complex interplay between intestinal inflammation in pediatric patients with Crohn's disease and the expression of *PXR, VIL1,* and *CYP3A4* in the GI tract. Prospective studies will differentiate whether our observations have a structural (e.g., tissue damage/loss) or a mechanistic (e.g., disease modification) basis. In the meantime, our data raise the question of what happens to PXR, its target genes, epithelial cell repair mechanisms, and mucosal healing when PXR is exogenously activated by ligands. Adult studies exploring the utility of PXR agonists (e.g., rifaximin) in the treatment of IBD are ongoing ([@B6]). Further exploration of PXR's potential as a novel/adjunct therapeutic target in pediatric Crohn's disease is warranted.
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